VIVUS

CompanyUnited StatesFounded 1991

RORWikidata

VIVUS develops 6 assets, the furthest approved (PANCREAZE in exocrine pancreatic insufficiency due to cystic fibrosis or other conditions). Mostly small molecule and protein or enzyme acting on PDE5A; based in the United States, founded in 1991.

6
Assets
Furthest stage
Approved
32
Trials
10
Signals

Pipeline

6
  • PANCREAZE

    Provides pancreatic enzyme therapy.

    Approved, Protein or enzyme, exocrine pancreatic insufficiency due to cystic fibrosis or other conditions

  • phentermine/topiramate

    Combines phentermine-mediated appetite suppression with topiramate to reduce food intake and promote weight loss.

    Approved, Small molecule, obesity, excess body weight

  • QSIVA

    Approved, Small molecule, excess body weight, obesity

3 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms6
  • Trials33
  • Signals20
  • Similar companies6

Papers

Intelligence